IKT
Inhibikase Therapeutics Inc
NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY
$1.93
-0.52% today
Updated 2026-05-05
Market cap
$254.82M
P/E ratio
—
P/S ratio
10.39x
EPS (TTM)
$-0.49
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
Inhibikase Therapeutics Inc (IKT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-36.00%
ROA
-20.50%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | $967386.00 | $-628737.00 | 12.51% | -63.40% | -64.99% |
| 2017 | $2.06M | $-436075.00 | 14.81% | -19.66% | -21.16% |
| 2018 | $4.04M | $-2.15M | 100.00% | -52.52% | -53.27% |
| 2019 | $1.12M | $-5.75M | -127.36% | -507.52% | -511.95% |
| 2020 | $698468.00 | $-2.88M | 100.00% | -403.52% | -411.94% |
| 2021 | $3.10M | $-14.81M | 100.00% | -476.23% | -477.52% |
| 2022 | $123440.00 | $-18.05M | 94.55% | -14,686.17% | -14,625.85% |
| 2023 | $260500.00 | $-19.03M | -5,127.77% | -7,712.01% | -7,304.75% |
| 2024 | $0.00 | $-27.52M | — | — | — |
| 2025 | $0.00 | $-48.26M | — | — | — |